1 Introduction to Research & Analysis Reports
1.1 Hemophilia Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hemophilia Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hemophilia Treatment Overall Market Size
2.1 Global Hemophilia Treatment Market Size: 2022 VS 2029
2.2 Global Hemophilia Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hemophilia Treatment Players in Global Market
3.2 Top Global Hemophilia Treatment Companies Ranked by Revenue
3.3 Global Hemophilia Treatment Revenue by Companies
3.4 Top 3 and Top 5 Hemophilia Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Hemophilia Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hemophilia Treatment Players in Global Market
3.6.1 List of Global Tier 1 Hemophilia Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Hemophilia Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Hemophilia Treatment Market Size Markets, 2022 & 2029
4.1.2 On-demand
4.1.3 Prophylaxis
4.2 By Type – Global Hemophilia Treatment Revenue & Forecasts
4.2.1 By Type – Global Hemophilia Treatment Revenue, 2018-2023
4.2.2 By Type – Global Hemophilia Treatment Revenue, 2024-2029
4.2.3 By Type – Global Hemophilia Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Hemophilia Treatment Market Size, 2022 & 2029
5.1.2 Replacement Therapy
5.1.3 ITI Therapy
5.1.4 Gene Therapy
5.2 By Application – Global Hemophilia Treatment Revenue & Forecasts
5.2.1 By Application – Global Hemophilia Treatment Revenue, 2018-2023
5.2.2 By Application – Global Hemophilia Treatment Revenue, 2024-2029
5.2.3 By Application – Global Hemophilia Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Hemophilia Treatment Market Size, 2022 & 2029
6.2 By Region – Global Hemophilia Treatment Revenue & Forecasts
6.2.1 By Region – Global Hemophilia Treatment Revenue, 2018-2023
6.2.2 By Region – Global Hemophilia Treatment Revenue, 2024-2029
6.2.3 By Region – Global Hemophilia Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Hemophilia Treatment Revenue, 2018-2029
6.3.2 US Hemophilia Treatment Market Size, 2018-2029
6.3.3 Canada Hemophilia Treatment Market Size, 2018-2029
6.3.4 Mexico Hemophilia Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Hemophilia Treatment Revenue, 2018-2029
6.4.2 Germany Hemophilia Treatment Market Size, 2018-2029
6.4.3 France Hemophilia Treatment Market Size, 2018-2029
6.4.4 U.K. Hemophilia Treatment Market Size, 2018-2029
6.4.5 Italy Hemophilia Treatment Market Size, 2018-2029
6.4.6 Russia Hemophilia Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Hemophilia Treatment Market Size, 2018-2029
6.4.8 Benelux Hemophilia Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Hemophilia Treatment Revenue, 2018-2029
6.5.2 China Hemophilia Treatment Market Size, 2018-2029
6.5.3 Japan Hemophilia Treatment Market Size, 2018-2029
6.5.4 South Korea Hemophilia Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Hemophilia Treatment Market Size, 2018-2029
6.5.6 India Hemophilia Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Hemophilia Treatment Revenue, 2018-2029
6.6.2 Brazil Hemophilia Treatment Market Size, 2018-2029
6.6.3 Argentina Hemophilia Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Hemophilia Treatment Revenue, 2018-2029
6.7.2 Turkey Hemophilia Treatment Market Size, 2018-2029
6.7.3 Israel Hemophilia Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Hemophilia Treatment Market Size, 2018-2029
6.7.5 UAE Hemophilia Treatment Market Size, 2018-2029
7 Hemophilia Treatment Companies Profiles
7.1 CSL Behring
7.1.1 CSL Behring Company Summary
7.1.2 CSL Behring Business Overview
7.1.3 CSL Behring Hemophilia Treatment Major Product Offerings
7.1.4 CSL Behring Hemophilia Treatment Revenue in Global Market (2018-2023)
7.1.5 CSL Behring Key News & Latest Developments
7.2 Baxalta
7.2.1 Baxalta Company Summary
7.2.2 Baxalta Business Overview
7.2.3 Baxalta Hemophilia Treatment Major Product Offerings
7.2.4 Baxalta Hemophilia Treatment Revenue in Global Market (2018-2023)
7.2.5 Baxalta Key News & Latest Developments
7.3 Pfizer Inc
7.3.1 Pfizer Inc Company Summary
7.3.2 Pfizer Inc Business Overview
7.3.3 Pfizer Inc Hemophilia Treatment Major Product Offerings
7.3.4 Pfizer Inc Hemophilia Treatment Revenue in Global Market (2018-2023)
7.3.5 Pfizer Inc Key News & Latest Developments
7.4 BioMarin
7.4.1 BioMarin Company Summary
7.4.2 BioMarin Business Overview
7.4.3 BioMarin Hemophilia Treatment Major Product Offerings
7.4.4 BioMarin Hemophilia Treatment Revenue in Global Market (2018-2023)
7.4.5 BioMarin Key News & Latest Developments
7.5 Bayer Healthcare
7.5.1 Bayer Healthcare Company Summary
7.5.2 Bayer Healthcare Business Overview
7.5.3 Bayer Healthcare Hemophilia Treatment Major Product Offerings
7.5.4 Bayer Healthcare Hemophilia Treatment Revenue in Global Market (2018-2023)
7.5.5 Bayer Healthcare Key News & Latest Developments
7.6 Biogen
7.6.1 Biogen Company Summary
7.6.2 Biogen Business Overview
7.6.3 Biogen Hemophilia Treatment Major Product Offerings
7.6.4 Biogen Hemophilia Treatment Revenue in Global Market (2018-2023)
7.6.5 Biogen Key News & Latest Developments
7.7 Novo Nordisk
7.7.1 Novo Nordisk Company Summary
7.7.2 Novo Nordisk Business Overview
7.7.3 Novo Nordisk Hemophilia Treatment Major Product Offerings
7.7.4 Novo Nordisk Hemophilia Treatment Revenue in Global Market (2018-2023)
7.7.5 Novo Nordisk Key News & Latest Developments
7.8 Roche
7.8.1 Roche Company Summary
7.8.2 Roche Business Overview
7.8.3 Roche Hemophilia Treatment Major Product Offerings
7.8.4 Roche Hemophilia Treatment Revenue in Global Market (2018-2023)
7.8.5 Roche Key News & Latest Developments
7.9 Takeda
7.9.1 Takeda Company Summary
7.9.2 Takeda Business Overview
7.9.3 Takeda Hemophilia Treatment Major Product Offerings
7.9.4 Takeda Hemophilia Treatment Revenue in Global Market (2018-2023)
7.9.5 Takeda Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
世界の血友病治療市場予測2023-2029：オンデマンド、予防 |
| 【英語タイトル】Hemophilia Treatment Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5609 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：65 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の血友病治療市場規模と予測を収録しています。・世界の血友病治療市場：売上、2018年-2023年、2024年-2029年 ・世界の血友病治療市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の血友病治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「オンデマンド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 血友病治療のグローバル主要企業は、CSL Behring、 Baxalta、 Pfizer Inc、 BioMarin、 Bayer Healthcare、 Biogen、 Novo Nordisk、 Roche、 Takedaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、血友病治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の血友病治療市場：タイプ別、2018年-2023年、2024年-2029年 世界の血友病治療市場：タイプ別市場シェア、2022年 ・オンデマンド、予防 世界の血友病治療市場：用途別、2018年-2023年、2024年-2029年 世界の血友病治療市場：用途別市場シェア、2022年 ・補充療法、ITI療法、遺伝子療法 世界の血友病治療市場：地域・国別、2018年-2023年、2024年-2029年 世界の血友病治療市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における血友病治療のグローバル売上、2018年-2023年 ・主要企業における血友病治療のグローバル売上シェア、2022年 ・主要企業における血友病治療のグローバル販売量、2018年-2023年 ・主要企業における血友病治療のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 CSL Behring、 Baxalta、 Pfizer Inc、 BioMarin、 Bayer Healthcare、 Biogen、 Novo Nordisk、 Roche、 Takeda ************************************************************* ・調査・分析レポートの概要 血友病治療市場の定義 市場セグメント 世界の血友病治療市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の血友病治療市場規模 世界の血友病治療市場規模：2022年 VS 2029年 世界の血友病治療市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの血友病治療の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の血友病治療製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：オンデマンド、予防 血友病治療のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：補充療法、ITI療法、遺伝子療法 血友病治療の用途別グローバル売上・予測 ・地域別市場分析 地域別血友病治療市場規模 2022年と2029年 地域別血友病治療売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） CSL Behring、 Baxalta、 Pfizer Inc、 BioMarin、 Bayer Healthcare、 Biogen、 Novo Nordisk、 Roche、 Takeda ... |
Hemophilia is a hereditary genetic disorder which impairs body’s ability to control coagulation or blood clotting. In this disease, clotting factors control bleeding from a broken vessel is deficient; therefore, coagulation does not occur. Of the two types of hemophilia, hemophilia A has higher prevalence compared to the other variant hemophilia B. . Acquired hemophilia is a rare non genetic form of hemophilia in which autoantibodies develop against the plasma coagulation factor. The development of novel coagulating factors and technological advancements are driving the growth of this market. Lack of available medicines, awareness of this disease and high cost of treatment are the major restraining factors in this market. The advancements in gene Therapy and approaching approval of drugs for treatment of hemophilia provide growth opportunities in this market.
This report aims to provide a comprehensive presentation of the global market for Hemophilia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hemophilia Treatment. This report contains market size and forecasts of Hemophilia Treatment in global, including the following market information:
Global Hemophilia Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hemophilia Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
On-demand Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hemophilia Treatment include CSL Behring, Baxalta, Pfizer Inc, BioMarin, Bayer Healthcare, Biogen, Novo Nordisk, Roche and Takeda, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hemophilia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hemophilia Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hemophilia Treatment Market Segment Percentages, by Type, 2022 (%)
On-demand
Prophylaxis
Global Hemophilia Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hemophilia Treatment Market Segment Percentages, by Application, 2022 (%)
Replacement Therapy
ITI Therapy
Gene Therapy
Global Hemophilia Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hemophilia Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hemophilia Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hemophilia Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
CSL Behring
Baxalta
Pfizer Inc
BioMarin
Bayer Healthcare
Biogen
Novo Nordisk
Roche
Takeda
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hemophilia Treatment, market overview.
Chapter 2: Global Hemophilia Treatment market size in revenue.
Chapter 3: Detailed analysis of Hemophilia Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hemophilia Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の血友病治療市場予測2023-2029：オンデマンド、予防] (コード：MMG23JU5609)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の血友病治療市場予測2023-2029：オンデマンド、予防]についてメールでお問い合わせ |
